Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. LEXX
LEXX logo

LEXX Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Lexaria Bioscience Corp (LEXX) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Sell
Latest Price
0.530
1 Day change
-5.18%
52 Week Range
1.550
Analysis Updated At
2026/07/03
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

LEXX is not a good buy right now for a beginner, long-term investor with $50,000-$100,000 to invest. The stock is trading below its pivot and under bearish moving averages, with no recent news, no bullish proprietary signal, and no clear financial upside shown in the provided data. My direct view is to avoid buying now.

Technical Analysis

Short-term momentum is weak. The price at 0.5708 is below the pivot level of 0.576, while the moving average structure is bearish with SMA_200 > SMA_20 > SMA_5. RSI_6 at 45.179 is neutral, so there is no oversold bounce signal. MACD histogram is slightly positive and expanding, which is the only mildly constructive sign, but it is not strong enough to override the bearish trend structure. Support is near 0.534 and 0.508, while resistance is at 0.618 and 0.644. Overall, the chart still looks weak.

Positive Catalysts

  • ["MACD histogram is positive and expanding", "Post-market move was positive at 1.91%", "Possible near-term bounce if price reclaims the pivot at 0.576"]

Neutral/Negative Catalysts

  • ["No news in the recent week", "Bearish moving average structure", "No AI Stock Picker signal today", "No SwingMax signal recently", "Hedge funds neutral with no significant trading trend", "Insiders neutral with no significant trading trend", "No recent congress trading data", "No valuation data provided", "Analyst sentiment and price target trend data not provided"]

Financial Performance

No usable latest-quarter financial snapshot was provided, so there is no clear evidence of revenue growth, profitability improvement, or recent quarter season performance to support a long-term buy thesis.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating or price target change data was provided. Based on the available information, Wall Street support appears weak to neutral because there are no recent favorable revisions, no price target momentum, and no visible catalyst from analysts.

Wall Street analysts forecast LEXX stock price to rise
1 Analyst Rating
Wall Street analysts forecast LEXX stock price to rise
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.559
sliders
Low
1.5
Averages
1.5
High
1.5
Current: 0.559
sliders
Low
1.5
Averages
1.5
High
1.5
H.C. Wainwright
Yi Chen
Buy
downgrade
$4
AI Analysis
2025-12-26
Reason
H.C. Wainwright
Yi Chen
Price Target
$4
AI Analysis
2025-12-26
downgrade
Buy
Reason
H.C. Wainwright analyst Yi Chen lowered the firm's price target on Lexaria Bioscience to $1.50 from $4 and keeps a Buy rating on the shares after the company reported final results from the Phase 1b GLP-1-H24-4 study recently completed in Australia. DehydraTECH-semaglutide reduced overall side-effects by 48% compared to Rybelsus, but performance in body weight reduction was not as robust as Rybelsus, the analyst tells investors in a research note.
H.C. Wainwright
Yi Chen
Buy
downgrade
$5 -> $4
2025-07-29
Reason
H.C. Wainwright
Yi Chen
Price Target
$5 -> $4
2025-07-29
downgrade
Buy
Reason
H.C. Wainwright analyst Yi Chen lowered the firm's price target on Lexaria Bioscience to $4 from $5 and keeps a Buy rating on the shares after the company reported interim results from the Phase 1b GLP-1-H24-4 study currently underway in Australia. The firm says DehydraTECH-semaglutide has demonstrated a favorable safety and tolerability profile.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for LEXX
Unlock Now

People Also Watch